Global Anti-Tuberculosis Therapeutics Market to grow with a CAGR of 5.90%.
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the Global Anti-Tuberculosis Therapeutics Market.
According to TechSci Research
report, “Global Anti-Tuberculosis Therapeutics Market Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2018-2028”, Global Anti-Tuberculosis
Therapeutics Market has valued at USD 1320.50 million in 2022 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 5.90% through 2028. This can be due to collaborations and partnerships among
leading companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market.
Epidemiological shifts drive
the demand for global anti-tuberculosis (TB) therapeutics. Changes in the
epidemiology of TB have a significant impact on the demand for TB drugs and
treatment strategies. As TB epidemiology evolves, new regions or countries may
emerge as TB hotspots with high TB incidence rates. These areas often require
increased resources for TB diagnosis, treatment, and control, leading to
greater demand for anti-TB medications. Urbanization and population
movement can lead to shifts in TB epidemiology. Rapidly growing urban areas may
experience higher TB transmission rates, requiring enhanced TB control efforts
and access to therapeutics. In some regions, aging populations may experience
higher rates of TB reactivation due to waning immunity. This demographic shift
can result in increased demand for TB therapeutics among older adults. Countries
with the highest TB burdens often have the greatest demand for anti-TB
therapeutics. Targeted interventions, funding, and access to medications are
essential to manage and reduce the disease burden in these countries. Advances
in genomic epidemiology allow for the tracking of TB strains and transmission
patterns. This information helps identify high-risk populations and guides
targeted interventions, including the provision of TB medications.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Anti-Tuberculosis Therapeutics Market”
Tuberculosis
(TB) is an infectious disease that primarily affects the lungs but can also
extend to other organs like the spine and brain. It is caused by Mycobacterium
tuberculosis, a type of bacteria. Pharmaceutical companies are intensifying
their research to develop drugs that can shorten treatment duration and address
the challenges posed by drug-susceptible and drug-resistant TB. Treatment for
TB can be categorized into first-line, second-line, and drug-resistant
treatments.
In
March 2022, as part of its commitment to the Corporate TB Pledge, a joint
initiative with the Central TB Division, Ministry of Health and Family Welfare
in India, and United States Agency for International Development (USAID),
Johnson & Johnson India announced the launch of a youth-focused,
digital-first initiative #BeTheChangeForTB. This initiative supports the Indian
Government's goal to end TB. The #BeTheChangeForTB program targets young people
in India since they are most suited to lead the public in changing their
behaviors, which would help to dramatically scale-up the battle against
tuberculosis. The project will also dispel popular myths about TB and provide
the correct information on the diagnosis and treatment of the illness. The
initiative's communication and social mobilization components would involve a
variety of online and offline activities, as well as collaboration with state
and district health agencies, the National Tuberculosis Elimination Program
(NTEP), and local neighborhoods.
Co-infection
with HIV (Human Immunodeficiency Virus) is a significant challenge in the
global anti-tuberculosis (TB) therapeutics market. HIV
weakens the immune system, making individuals more susceptible to TB infection.
HIV-infected individuals are at a much higher risk of developing active TB
disease if they are exposed to TB bacteria. TB and HIV often present with
similar symptoms, such as cough, fever, and weight loss. This can lead to
delayed diagnosis and treatment for both diseases, as healthcare providers may
not immediately recognize the possibility of co-infection. Treating co-infected individuals can be
challenging due to potential drug interactions between anti-TB medications and
antiretroviral therapy (ART) used to manage HIV. Some TB drugs, particularly
rifampin, can interfere with the effectiveness of certain HIV medications.
Co-infected individuals often require complex treatment regimens that
simultaneously address both TB and HIV. These regimens must be carefully
managed to ensure treatment effectiveness while minimizing adverse effects and
drug interactions.
Global Anti-Tuberculosis
Therapeutics Market segmentation is based on Disease Type, Diagnostic and
Treatment, End User, and Region.
Based on Disease Type, Global Anti-Tuberculosis
Therapeutics Market is segmented into Active TB, Latent TB, and Others. Latent tuberculosis infection (LTBI), often
referred to as latent TB, is a condition in which an individual has been
infected with the bacterium Mycobacterium tuberculosis but does not currently
exhibit active symptoms of tuberculosis disease. Instead, the TB bacteria
remain dormant or latent within the body. Individuals with latent
TB do not feel sick and do not experience the typical symptoms of active TB,
such as cough, chest pain, fever, night sweats, and weight loss. They generally
appear healthy and cannot spread TB to others. Latent TB represents an
infection with M. tuberculosis, but the immune system successfully contains the
bacteria. It is not a form of active TB disease. A diagnosis of latent TB is
typically confirmed through a positive reaction to a TB skin test (tuberculin
skin test, TST) or a blood test called an interferon-gamma release assay
(IGRA). These tests detect the presence of TB-specific proteins or antigens in
the body.
Based on Region, North America dominated the Global Anti-Tuberculosis
Therapeutics Market.
North America's relatively low TB burden is partly due to rigorous TB control
measures. However, the region's high levels of international travel and
migration mean that TB remains a concern, and robust control efforts are in
place to prevent its spread. North America has well-developed
healthcare infrastructure, including access to state-of-the-art diagnostic
tools and treatments. This enables early detection and effective treatment of
TB cases. Clinical trials for new anti-TB drugs often include North
American sites, and the U.S. Food and Drug Administration (FDA) plays a
critical role in drug approvals. Successful clinical trials and drug approvals contribute
to the global TB treatment arsenal.
Asia-pacific region to fastest growth in
the Global Anti-Tuberculosis Therapeutics Market. The APAC region has a
significant burden of TB cases, with several countries reporting high TB
incidence rates. This high prevalence of TB creates a substantial demand for
anti-TB therapeutics, including drugs and treatment regimens. APAC is the most
populous region in the world, with a large and diverse population. The sheer
number of people in the region means that even a moderate TB incidence rate can
result in a substantial number of TB cases, driving the demand for TB
therapeutics. Many countries in APAC are investing in expanding and
improving their healthcare infrastructure. This includes strengthening diagnostic
capabilities, expanding access to healthcare services, and enhancing the
availability of TB medications. Some countries in the APAC region, such as
India and China, have experienced rapid economic growth in recent years. This
has led to increased healthcare spending and greater access to TB treatment for
their populations.
Some of the major companies
operating in the Global Anti-Tuberculosis Therapeutics Market include:
- AstraZeneca Plc.
- Johnson & Johnson Private Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi SA
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
Download Free Sample Report
Customers can also request 10% free
customization on this report
“Certain
areas, particularly in North America, are projected to exert significant demand
for Tuberculosis treatment. The growth in the competitive landscape and the
presence of well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Anti-Tuberculosis Therapeutics Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Anti-Tuberculosis Therapeutics Market – Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2018-2028 Segmented by Disease Type (Active
TB, Latent TB, Others), by Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging
Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of
Drugs, others), others), by End User (Hospitals, Specialty Clinics, Homecare, others), by region, and Competition evaluated the future growth potential of Global
Anti-Tuberculosis Therapeutics Market and provides statistics & information
on market size, structure, and future market growth. The report intends to
provide innovative market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in Global
Anti-Tuberculosis Therapeutics Market.
Contact
Techsci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com